CTMX CytomX Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTMX

Price (delayed)

$1.63

Market cap

$107.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.49

Enterprise value

-$6.63M

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics, ...

Highlights
CTMX's debt is down by 19% year-on-year and by 6% since the previous quarter
CTMX's revenue is up by 9% year-on-year and by 2.7% since the previous quarter
CTMX's equity has dropped by 63% year-on-year and by 29% since the previous quarter
CytomX Therapeutics's net income has shrunk by 51% YoY and by 5% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cytomx.com
Peers: OVID OYST

Key stats

What are the main financial stats of CTMX
Market
Shares outstanding
65.95M
Market cap
$107.5M
Enterprise value
-$6.63M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.19
Price to sales (P/S)
1.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.09
Earnings
Revenue
$72.62M
EBIT
-$96.88M
EBITDA
-$91.05M
Free cash flow
-$138.1M
Per share
EPS
-$1.49
Free cash flow per share
-$2.11
Book value per share
$0.74
Revenue per share
$1.11
TBVPS
$3.94
Balance sheet
Total assets
$260.09M
Total liabilities
$211.38M
Debt
$16.08M
Equity
$48.71M
Working capital
$133.33M
Liquidity
Debt to equity
0.33
Current ratio
2.34
Quick ratio
2.31
Net debt/EBITDA
1.25
Margins
EBITDA margin
-125.4%
Gross margin
100%
Net margin
-133.4%
Operating margin
-134.5%
Efficiency
Return on assets
-30.6%
Return on equity
-121.9%
Return on invested capital
-211.3%
Return on capital employed
-60.3%
Return on sales
-133.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTMX stock price

How has the CytomX Therapeutics stock price performed over time
Intraday
-2.4%
1 week
2.52%
1 month
8.67%
1 year
-66.67%
YTD
-62.36%
QTD
-10.93%

Financial performance

How have CytomX Therapeutics's revenue and profit performed over time
Revenue
$72.62M
Gross profit
$72.62M
Operating income
-$97.66M
Net income
-$96.88M
Gross margin
100%
Net margin
-133.4%
The operating income has dropped by 51% year-on-year and by 6% since the previous quarter
CytomX Therapeutics's net income has shrunk by 51% YoY and by 5% QoQ
The company's operating margin fell by 39% YoY and by 3.3% QoQ
CTMX's net margin is down by 38% year-on-year and by 2.6% since the previous quarter

Growth

What is CytomX Therapeutics's growth rate over time

Valuation

What is CytomX Therapeutics stock price valuation
P/E
N/A
P/B
2.19
P/S
1.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.09
The EPS has contracted by 25% YoY and by 4.9% from the previous quarter
The stock's price to book (P/B) is 69% less than its 5-year quarterly average of 7.1 and 22% less than its last 4 quarters average of 2.8
CTMX's equity has dropped by 63% year-on-year and by 29% since the previous quarter
The stock's P/S is 79% less than its 5-year quarterly average of 7.0 and 55% less than its last 4 quarters average of 3.3
CTMX's revenue is up by 9% year-on-year and by 2.7% since the previous quarter

Efficiency

How efficient is CytomX Therapeutics business performance
The ROIC has shrunk by 142% YoY and by 20% QoQ
CTMX's return on assets has dropped by 87% year-on-year and by 17% since the previous quarter
CTMX's ROE has dropped by 78% year-on-year and by 33% since the previous quarter
The ROS has contracted by 38% YoY and by 2.6% from the previous quarter

Dividends

What is CTMX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTMX.

Financial health

How did CytomX Therapeutics financials performed over time
CTMX's total assets is 23% more than its total liabilities
CTMX's total assets is down by 35% YoY and by 12% from the previous quarter
The company's total liabilities fell by 22% YoY and by 8% QoQ
CTMX's debt is 67% smaller than its equity
The debt to equity has soared by 120% year-on-year and by 32% since the previous quarter
CTMX's equity has dropped by 63% year-on-year and by 29% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.